Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul-Aug;9(7-8):263-7.
doi: 10.5489/cuaj.2377.

Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma

Roberto Iacovelli  1 , Daniele Santini  1 , Mimma Rizzo  1 , Alessandra Felici  1 , Matteo Santoni  1 , Elena Verzoni  1 , Cristina Masini  1 , Francesco Massari  1 , Nicola Calvani  1 , Alessandra Mosca  1 , Giuseppe Procopio  2
Affiliations

Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma

Roberto Iacovelli et al. Can Urol Assoc J. 2015 Jul-Aug.

Abstract

Introduction: Treatment of metastatic renal cell carcinoma (mRCC) has improved with the use of targeted therapies, but bone metastases continue to be negative prognostic factor.

Methods: Patients with mRCC treated with everolimus (EV) or sorafenib (SO) after two previous lines of targeted therapies were included in the analysis. Overall survival (OS) and progression-free survival (PFS) were assessed based on the presence of bone metastases and type of therapy; they were also adjusted based on prognostic criteria.

Results: Of the 233 patients with mRCC, 76 had bone metastases. Of the 233 patients, EV and SO were administered in 143 and 90 patients, respectively. Median OS was 10.4 months in patients with BMs and 17.4 months in patients without bone metastases (p = 0.002). EV decreased the risk of death by 18% compared to SO (adjusted hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.74-0.91; p < 0.001), with comparable effects in patients with or without bone metastases. In the same manner, EV decreased the risk of progression by 12% compared to SO (adjusted HR 0.88, 95% CI 0.82-0.96; p = 0.002), but this difference was not significant in patients without bone metastases. The major limitations of the study are its retrospective nature, the heterogeneity of the methods to detect bone metastases, and the lack of data about patients treated with bisphosphonates.

Conclusions: The relative benefit of targeted therapies in mRCC is not affected by the presence of bone metastases, but patients without bone metastases have longer response to therapy and overall survival.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Overall survival based on presence of bone metastases.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Galasko C. The anatomy and pathways of skeletal metastases. In: Weiss L, Gilbert A, editors. Bone Metastases. Vol. 1981. GK Hall; Boston: pp. 49–63.
    1. Woodward E, Jagdev S, McParland L, et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 2011;48:160–6. doi: 10.1016/j.bone.2010.09.008. - DOI - PubMed
    1. Zekri J, Ahmed N, Coleman RE, et al. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 2001;19:379–82. doi: 10.3892/ijo.19.2.379. - DOI - PubMed
    1. Althausen P, Althausen A, Jennings LC, et al. Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer. 1997;80:1103–9. doi: 10.1002/(SICI)1097-0142(19970915)80:6<1103::AID-CNCR13>3.0.CO;2-C. - DOI - PubMed
    1. Koga S, Tsuda S, Nishikido M, et al. The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol. 2001;166:2126–8. doi: 10.1016/S0022-5347(05)65519-X. - DOI - PubMed

LinkOut - more resources